News
News Center
2020-01-23
As the vibrant 2020 Spring Festival approaches, Zhang Quancheng, Chairman of Meike Company, and Gao Yansong, General Manager, extend their warmest wishes on behalf of everyone at Jiuzhitang Maker! We sincerely thank each and every friend and family member who has shown care, support, affection, and attention to the growth of Jiuzhitang Maker. Wishing you all a joyful and prosperous New Year!
+
2020-01-23
Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd. recently received significant funding from Beijing's major science and technology project. The company's proposed project, "Preclinical Study of Human Bone Marrow Mesenchymal Stem Cells for the Treatment of Acute Stroke," has been officially approved (Project No. Z191100001519004).
+
2020-01-23
On January 14, 2020, the Zhongguancun Science Park Administrative Committee announced the ninth batch of Golden Seed Enterprise名单, and Jiuzhitang Maker was proudly listed!
+
2020-01-01
Looking back at 2019, Meike took every step with solid confidence and strength.
We're on the road.
+
2019-12-24
Ensuring Public Medication Safety: Jiuzhitang Makes a Solemn Commitment
In the future, Jiuzhitang will remain committed to addressing public health needs by continuously monitoring the quality standards and traceability of authentic medicinal materials in its existing product line. We will actively engage in research aimed at evaluating the clinical value of traditional Chinese medicine and assessing renowned classic prescriptions, all while striving to enhance product quality. At the same time, we will relentlessly innovate and develop new products, delivering even better healthcare solutions to the public.
+
2019-11-20
Jiuzhitang Maker's clinical trial application for a new stem-cell drug has been accepted.
This clinical trial application for Jiuzhitang Maker is the first submitted to the National Center for Drug Evaluation involving the use of imported stem cell products.
+
2019-11-05
Dr. Epstein suggested that repeated intravenous injections of MSCs may help control the persistent abnormal inflammation following left ventricular assist device implantation, thereby improving patients' myocardial function. Stem cell therapy holds promise as an effective approach for treating cardiovascular diseases.
+
2019-10-31
Jiuzhi Interview Room | I watched 100% of this ceremony! What impressed you the most?
What impressed you most about the National Day military parade?
+
2019-10-30
Mr. Li Zhenguo, Chairman of Jiuzhitang, said that innovation is the only path forward for the development of traditional Chinese medicine enterprises.
+
Here is the title—h1 placeholder text
Copyright © Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd.
Powered by: 300.cn SEO | Privacy Policy